For investors watching Alnylam Pharmaceuticals (ALNY), the latest HELIOS-B Phase 3 analyses of vutrisiran and reaffirmed transthyretin, or TTR, franchise revenue guidance have put fresh attention on how clinical evidence and commercial execution intersect for this stock.

These HELIOS-B data and reaffirmed TTR guidance arrive after a period where the share price has fallen 26.7% year to date on a share price basis, even as the 5 year total shareholder return is 109.46%. This suggests long term holders have still seen sizeable gains despite recent pressure.

If this kind of biotech catalyst has your attention, it could be a good moment to see what else is moving using our screener for 34 healthcare AI stocks

With Alnylam’s share price down 26.7% year to date despite a 5 year total return above 100%, reaffirmed TTR guidance and fresh HELIOS-B data raise a key question: is this a buying opportunity or is future growth already priced in?

Most Popular Narrative: 40.3% Undervalued

Compared with the last close at $293.45, the most followed narrative puts Alnylam’s fair value at about $491.92, framing the HELIOS B story inside a much larger TTR and pipeline view.

The rapid and robust uptake of AMVUTTRA for ATTR-CM in its first full quarter post-approval, combined with near-universal first-line payer access and minimal patient out-of-pocket costs, indicates a much larger addressable market for Alnylam's RNAi therapies as diagnostics and disease awareness improve, supporting sustained double-digit revenue growth.

Curious what has to happen for that valuation gap to close? The key ingredients are faster revenue expansion, rising margins and a future profit multiple that assumes real staying power.

All of this is run through a discount rate of about 7.1%, which is used to bring those future cash flows and earnings back into today’s dollars and produce the fair value estimate of roughly $491.92 per share.

Result: Fair Value of $491.92 (UNDERVALUED)

However, you also have to factor in the possibility that heavy reliance on the TTR franchise and ongoing pricing or reimbursement pressure could quickly change this story.

Another Way To Look At Valuation

The narrative model paints Alnylam as about 40% undervalued, yet the current P/E of 72.8x sits well above both the sector at 17.2x and a fair ratio of 29.6x, and peers at 29.8x. That kind of gap can mean rich expectations. Which signal matters more to you?

Next Steps

With mixed signals on value, growth and risk, it helps to see the full picture for yourself and move quickly from headlines to hard data by checking the 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Alnylam has sharpened your focus on where to put fresh capital to work, this is the moment to widen your search before the next wave of opportunities moves on.

• Target potential mispricings by scanning for quality stocks that look cheap on the numbers with the help of the 47 high quality undervalued stocks.
• Anchor your portfolio around companies that aim to keep paying you, using the 13 dividend fortresses to spot higher yielding options.
• Protect your downside by concentrating on sturdier balance sheets and steadier fundamentals through the solid balance sheet and fundamentals stocks screener (45 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.